Induction therapy in acute myeloid leukemia: Intensifying and targeting the approach

Current Opinion in Hematology

Volumn 17, Issue 2, 2010, Pages 79-84

  Fernandez, Hugo F ^a   Rowe, Jacob M ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Acute myeloid leukemia; Dose intensification; Induction therapy; Targeted therapy

Indexed keywords

ARSENIC TRIOXIDE; AZACITIDINE; BORTEZOMIB; CHEMOKINE RECEPTOR CXCR4; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLT3 LIGAND; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LONAFARNIB; MIDOSTAURIN; MITOXANTRONE; STROMAL CELL DERIVED FACTOR 1; TIPIFARNIB; VASCULOTROPIN; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG TARGETING; HUMAN; LOW DRUG DOSE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW;

AMINOGLYCOSIDES; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 76749154506     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283366b7a     Document Type: Review

References (41)

1. American Cancer Society. Cancer facts & figures 2008. 2008 ACS, Atlanta, Georgia. http://www.cancer.org. Accessed 1 October 2009.
2. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301:2349-2361.
3. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109:3658-3666.
4. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909-1918.
5. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973; 57:485-488.
6. Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood 1987; 69:1441-1449.
7. Schiller G, Gajewski J, Nimer S, et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol 1992; 81:170-177.
8. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88:2841-2851.
9. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 2004; 22:4290-4301.
10. Castaigne S, Chevret S, Archimbaud E, et al. Randomized comparison of double induction and timed-sequential induction to a '3 + 7' induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004; 104:2467-2474.
11. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361:1249-1259.
12. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996; 87:4979-4989.
13. Buchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative group. J Clin Oncol 2003; 21:4496-4504.
14. Braess J, Spiekermann K, Staib P, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 2009; 113:3903-3910.
15. Burke PJ, Vaughan WP, Karp JE. A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation. Blood 1980; 55:960-968.
16. Vaughan WP, Karp JE, Burke PJ. Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 1984; 64:975-980.
17. Rowe JM, Tallman MS. Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? Blood 1997; 90:2121-2126.
18. Kalaycio M, Advani A, Pohlman B, et al. Timed sequential induction che-motherapy and risk-adapted postremission therapy for acute myelogenous leukemia. Am J Hematol 2008; 83:831-834.
19. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003; 102:4277-4283.
20. Burnett AK, Kell WJ, Goldstone AH, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRCAML15 trial. Blood (ASH Annual Meeting Abstracts) 2006; 108:A-13.
21. Candoni A, Martinelli G, Toffoletti E, et al. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Res 2008; 32:1800-1808.
22. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative group. J Clin Oncol 2009; 27:61-69.
23. Burnett AK, Milligan D, Goldstone A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009; 145:318-332.
24. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113:4179-4187.
25. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86:457-462.
26. Rowe JM, Neuberg D, Friedenberg W, et al.A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103:479-485.
27. Lowenberg B, OssenkoppeleGJ,van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361:1235-1248.
28. Latagliata R, Breccia M, Fazi P, et al. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMAGSI103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol 2008; 143:681-689.
29. Roboz GJ, Ritchie EK, Curcio T, et al. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 2008; 113:2504-2511.
30. Erba HP, Kantarjian HM, Claxton D, et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. J Clin Oncol (Meeting Abstracts) 2008; 26 (Suppl 15):7025.
31. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112:1638-1645.
32. Barry EV, Clark JJ, Cools J, et al. Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. Blood 2007; 110:4476-4479.
33. Willman CL. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Leukemia 1996; 10 (Suppl 1):S33-S35.
34. Lancet JE, Baer MR, Duran GE, et al. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytara bine in acute myeloid leukemia. Leuk Res 2009; 33:1055-1061.
35. Cripe LD, Li X, Litzow M, et al. A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for pts > 60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999. Blood (ASH Annual Meeting Abstracts) 2006; 108:A-423.
36. Harousseau JL, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009; 114:1166-1173.
37. Altucci L, Minucci S. Epigenetic therapies in haematological malignancies: searching for true targets. Eur J Cancer 2009; 45:1137-1145.
38. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment inleukemia and other cancers. Leukemia 2009; 23:43-52.
39. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizu-mab. Clin Cancer Res 2004; 10:3577-3585.
40. Zahiragic L, Schliemann C, Bieker R, et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007; 21:1 310-131 2.
41. Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008; 14: 1446-1454.